Clinical Scorecard: Tracking Development from Fetal Stage to Age 8: Insights from the CHILD Cohort Study
At a Glance
Category
Detail
Condition
Development of chronic noncommunicable diseases including asthma, allergies, obesity, cardiometabolic and neurodevelopmental outcomes
Key Mechanisms
Interactions between early life physical and psychosocial environments with biological factors (immunologic, genetic, physiologic, metabolic)
Target Population
Canadian infants from fetal life through childhood and adolescence
Care Setting
Multicenter longitudinal population-based cohort with clinical assessments and home visits
Key Highlights
Longitudinal prospective cohort following 3454 infants from fetal life to age 8 and beyond with 90.7% retention at 8 years
Comprehensive data collection including clinical phenotyping, environmental sampling, microbiome, genetics, epigenetics, nutrition, and actigraphy
Expanded scope beyond asthma and allergies to include growth, obesity, cardiovascular health, infections, neurodevelopment, and mental health
Guideline-Based Recommendations
Diagnosis
Use detailed clinical and physiologic phenotyping at strategic intervals from prenatal to adolescence
Incorporate environmental, genetic, epigenetic, and microbiome assessments for comprehensive evaluation
Management
Monitor early life exposures and biological factors to identify risk for chronic noncommunicable diseases
Implement precision medicine approaches based on integrated omics and environmental data
Monitoring & Follow-up
Conduct repeated longitudinal assessments including questionnaires, interviews, physical exams, allergy and lung function tests
Utilize virtual visits as needed to maintain data collection continuity during disruptions (e.g., COVID-19 pandemic)
Risks
Exclude preterm births (<34 weeks +4 days), multiple pregnancies, major congenital abnormalities, and infants with respiratory distress syndrome for cohort consistency
Consider potential impact of environmental and psychosocial factors on disease development
Patient & Prescribing Data
General population infants recruited during pregnancy in Canada
Data platform supports identification of early life risk factors to inform prevention and treatment strategies for asthma, allergies, obesity, and neurodevelopmental disorders
Clinical Best Practices
Recruit pregnant women at midpregnancy (18-25 weeks gestation) for early life exposure assessment
Maintain high retention rates through participant engagement and flexible data collection methods
Integrate multi-omics data with environmental and clinical phenotyping for comprehensive disease risk profiling
Implement subcohorts to study emerging health issues such as SARS-CoV-2 infection and pandemic impacts
by Kozeta Miliku, Myrtha E Reyna, Maria Medeleanu, Ruixue Dai, Aimee Dubeau, Diana L Lefebvre, Kim Wright, Bassel Dawod, Marshall Beck, Elissa Brooks, Michael Kobor, Qingling Duan, Jeffrey R Brook, Wendy Lou, Fiona S L Brinkman, Geoffrey L Winsor, Justin Cook, Allan B Becker, Elinor Simons, Piushkumar J Mandhane, Theo J Moraes, Meghan B Azad, Malcolm R Sears, Stuart E Turvey, Padmaja Subbarao, The CHILD Study Investigators
